These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 27421997)

  • 21. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
    Xu J; Sun HH; Fletcher CD; Hornick JL; Morgan EA; Freeman GJ; Hodi FS; Pinkus GS; Rodig SJ
    Am J Surg Pathol; 2016 Apr; 40(4):443-53. PubMed ID: 26752545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma.
    Kucukgoz Gulec U; Kilic Bagir E; Paydas S; Guzel AB; Gumurdulu D; Vardar MA
    Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():51-55. PubMed ID: 31739121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed Cell Death Ligand 1 Expression in Canine Cancer.
    Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T
    In Vivo; 2016; 30(3):195-204. PubMed ID: 27107075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.
    Boxberg M; Steiger K; Lenze U; Rechl H; von Eisenhart-Rothe R; Wörtler K; Weichert W; Langer R; Specht K
    Oncoimmunology; 2018; 7(3):e1389366. PubMed ID: 29399389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
    Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
    Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.
    Yvorel V; Patoir A; Casteillo F; Tissot C; Fournel P; Stachowicz ML; Karpathiou G; Tiffet O; Péoc'h M; Forest F
    PLoS One; 2017; 12(7):e0180346. PubMed ID: 28671973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
    Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
    Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
    Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
    Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
    Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T
    J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.
    Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E
    Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
    Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH
    Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
    He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
    Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
    Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
    Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
    J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
    Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
    JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
    Vargas AC; Maclean FM; Sioson L; Tran D; Bonar F; Mahar A; Cheah AL; Russell P; Grimison P; Richardson L; Gill AJ
    PLoS One; 2020; 15(4):e0222551. PubMed ID: 32294103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.